Charlottesville, June 10, 2014 Biovista announces online environment for in-context selling of life science products Biovista announced today the availability of its viz.it solution. Aimed at reagent and life-sciences product companies viz.it integrates seamlessly with customer web sites and their online product catalogs and payment systems. Short for “visualize it”, viz.it lets scientists/researchers browse through … Read More
Announcements
Biovista Featured in CHI’s InsightPharma Report on Drug Repositioning
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning. The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the … Read More
Biovista delivers critical data for the CTSA Pharmaceutical Assets Portal
Charlottesville, VA, 12 February 2009 In recent years the life sciences community is seeing increasing evidence showing that drugs that have failed as a cure for one disease may hold promise for a different condition. An academic consortium led by UC Davis is now leading a collaborative effort, called the Pharmaceutical Assets Portal, to allow … Read More
Biovista Nutrition application released for the Apple iPhone
Charlottesville, January 28, 2009 Biovista announced today the availability of its Biovista Nutrition application for the Apple iPhone. Biovista Nutrition for the iPhone (BNi) provides information on the interaction of nutritional supplements with drugs and diseases. “We are pleased to have launched this mobile application that can provide useful first level information to consumers at … Read More
Biovista initiates its Macular Degeneration and CNS drug repositioning programs.
Charlottesville, VA and Athens, Greece. Biovista began work today on two internal programs aimed to reposition marketed drugs or drugs in Phase II/III in Macular Degeneration and CNS. Biovista has already identified a number of candidates with the requisite biological plausibility that are also unencumbered by prior patent filings or prior art. The Company is … Read More